But, at the same time, they presented an analysis by Oxford University's Sir Richard Peto, who argued there is "no credible evidence" of a link between the active ingredient in Vytorin and Zetia and cancer.
In a strongly worded editorial, the New England Journal of Medicine took issue with an analysis that had dismissed a link between an active ingredient in the pills and cancer.